Stay updated on SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.

Latest updates to the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedA new consolidated Locations section lists participating sites across California, Colorado, Kentucky, Michigan, New York, Pennsylvania, South Dakota, Texas, and Utah, replacing the prior per-state headings. The footer revision note also updates from v3.3.2 to v3.3.3.SummaryDifference0.9%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedRevision: v3.3.2 is now displayed on the page, replacing v3.2.0. This update is limited to a software/version change and does not alter study details or other user-visible content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check45 days agoChange DetectedRemoved a general government funding status notice from the page; this banner is administrative and does not affect trial details or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check67 days agoChange DetectedThe changes are limited to minor formatting and small textual tweaks; core study content such as design, eligibility criteria, and endpoints remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check88 days agoChange DetectedUpdate to v3.2.0 with an important government-operating-status notice; removal of two GARD resources (Carcinoma of esophagus and Cutaneous neuroendocrine carcinoma) from the catalog.SummaryDifference4%

- Check96 days agoChange DetectedPage now shows Revision: v3.1.0 and removes the topic term 'Ovarian cancer' from the content, signaling a scope/content update with versioned revision rather than a data-heavy update.SummaryDifference0.2%

Stay in the know with updates to SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNS-101 and Cemiplimab Combo in Solid Tumors Clinical Trial page.